mocertatug rezetecan (GSK5733584) / Jiangsu Hansoh Pharma, GSK - LARVOL DELTA

BEHOLD-Ovarian01: A Phase 3 randomised trial to evaluate mocertatug rezetecan (Mo-Rez) versus standard of care (SoC) in patients (pts) with platinum-resistant ovarian cancer (PROC) (ESMO 2026) - No abstract available

Clinical • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

BEHOLD-Endometrial01: A randomised Phase 3 study evaluating the efficacy and safety of mocertatug rezetecan (Mo-Rez) versus chemotherapy in patients with advanced or recurrent endometrial cancer after platinum-based therapy and immunotherapy (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Endometrial Cancer • Oncology • Solid Tumor

BEHOLD-1: Exploratory analysis of biomarkers associated with mocertatug rezetecan (Mo-Rez) response in patients with platinum-resistant ovarian cancer (PROC) (ESMO 2026) - No abstract available

Biomarker • Clinical • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Mocertatug rezetecan (Mo-Rez) in patients with platinum-resistant ovarian cancer (PROC): Updated results with longer follow-up from the global BEHOLD-1 study (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Platinum resistant • Gynecologic Cancers • Oncology • Ovarian Cancer

HS-20089 PSOC: Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - P3 | N=460 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P3 trial • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (ESMO 2023) - P1 | "The patient achieving PR with the longest treatment duration of 403 days remains on treatment in 0.7 mg/kg cohort. Conclusions Based on data from the ongoing study, HS-20089 was well tolerated and showed antitumor activities in advanced solid tumors, with encouraging clinical efficacy in TNBC."

Clinical • Metastases • P1 data • Breast Cancer • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • VTCN1

Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study (ESMO-Gynae 2026) - P1, P3 | "Mo-Rez 5.8 mg/kg Q3W will be evaluated in global phase III trials (PROC: NCT07286266; advanced/recurrent EC: NCT07286331). Legal entity responsible for the study GSK (GSK study 222730)"

ADC • Platinum resistant • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • PARP1 • VTCN1

BEHOLD-2: A phase I/II randomized study evaluating mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with anti-cancer agents in patients with solid tumors (ESMO Asia 2025) - P1/2 | "GSK'584 will be combined with dostarlimab (500 mg every 3 weeks [Q3W]) in patients with EC (Module 1) and with bevacizumab (15 mg/kg Q3W) in patients with OC (Module 2). Wu J, et al. Ann Oncol 2023; 34(suppl2):Abstr3810."

Clinical • Combination therapy • P1/2 data • Endometrial Cancer • Oncology • Solid Tumor • VTCN1

Mocertatug rezetecan: Initiation of P3 BEHOLD-Endometrial02 trial (NCT07684599) for MMRp endometrial cancer in H2 2026 (GSK) - Q2 2026 Results

Trial initiation date • Endometrial Cancer • Gynecologic Cancers • Oncology

Mocertatug rezetecan: Initiation of P3 BEHOLD-Ovarian02 trial (NCT07684612) for platinum-sensitive ovarian cancer in H2 2026 (GSK) - Q2 2026 Results: Initiation of P3 BEHOLD-Ovarian01 trial (NCT07694427) for non-homologous recombination deficient ovarian cancer in H2 2026

Platinum sensitive • Trial initiation date • Gynecologic Cancers • Oncology • Ovarian Cancer

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient (News-Medical) - "The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial....BEHOLD-Ovarian01 is a randomized, open-label, multicenter Phase 3 study designed to determine whether Mo-Rez can improve outcomes compared with investigator's choice chemotherapy in patients with platinum-resistant ovarian cancer."

Enrollment open • Platinum resistant • Ovarian Cancer

Mocertatug-rezetecan (Mo-Rez; GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from BEHOLD-1 study (BGCS 2026) - P1 | "Conclusions Mo-Rez showed encouraging antitumour activity against PROC and EC with a manageable safety profile. Mo-Rez is being evaluated in Phase 3 trials in PROC and recurrent EC."

ADC • Platinum resistant • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • VTCN1

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Aug 2030 ➔ Dec 2029 | Trial primary completion date: Aug 2030 ➔ Dec 2029

Platinum resistant • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) (clinicaltrials.gov) - P3 | N=690 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) (clinicaltrials.gov) - P3 | N=610 | Not yet recruiting | Sponsor: GlaxoSmithKline

Checkpoint inhibition • Mismatch repair • New P3 trial • pMMR • Endometrial Cancer • Oncology • Solid Tumor

Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03] (clinicaltrials.gov) - P3 | N=720 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Oncology • Ovarian Cancer • Solid Tumor

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Endometrial Cancer • Oncology • Solid Tumor

BEHOLD-2: A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=305 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Apr 2028 ➔ Oct 2028 | Trial primary completion date: Dec 2027 ➔ Jun 2027

pMMR • Trial completion date • Trial primary completion date • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • VTCN1

BEHOLD-1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=675 | Recruiting | Sponsor: GlaxoSmithKline | N=385 ➔ 675 | Trial completion date: Sep 2027 ➔ Dec 2029 | Trial primary completion date: Feb 2027 ➔ Sep 2027

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Oncology • Solid Tumor • BRCA • FOLR1 • VTCN1

Non-clinical characterization of Mocertatug Rezetecan (GSK5733584), a novel B7-H4-directed antibody-drug conjugate (AACR 2026) - "Notably, Mo-Rez antitumor responses were observed in both homologous recombination deficient and proficient (HRD and HRP, respectively) ovarian cancer PDX models.Importantly, the strong antitumor activity in ovarian models align with recent clinical data for Mo-Rez in heavily pretreated platinum-resistant ovarian cancer (PROC, 48.5% ORR). Collectively, these findings support Mo-Rez as a promising cancer therapy and its rapidly progressing global clinical development (BEHOLD trials)."

ADC • Clinical • Biliary Cancer • Breast Cancer • Cervical Cancer • Cholangiocarcinoma • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD28 • HRD • TOP1 • VTCN1

BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer (AACR 2025) - P1 | "Tissue, blood, and urine samples will be collected for biomarker/PK evaluations. Results will be reported using descriptive statistics and 95% confidence intervals.This abstract was previously presented at SGO 2025.Funding: GSK (study 222730)."

ADC • Clinical • Metastases • P1 data • Platinum resistant • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16 • VTCN1

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jan 2030 ➔ Jul 2030 | Initiation date: Mar 2026 ➔ Jun 2026 | Trial primary completion date: Jan 2030 ➔ Jul 2030

Platinum resistant • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • VTCN1

Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study (SGO 2026) - No abstract available

ADC • Clinical • Late-breaking abstract • Platinum resistant • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • VTCN1

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01) (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: GlaxoSmithKline | Initiation date: Mar 2026 ➔ Jun 2026

Trial initiation date • Endometrial Cancer • Oncology • Solid Tumor • VTCN1